Cabaletta Bio, Inc. — Q1 2021 Form 10-Q Summary
Business context and reporting period
Cabaletta Bio is a clinical-stage biotechnology company developing engineered CAAR T-cell therapies for B-cell-mediated autoimmune diseases through its CABA platform. The filing covers the three months ended March 31, 2021, with comparative results for the three months ended March 31, 2020. The company has no approved products and has not generated revenue from product sales.
- Lead program: DSG3-CAART for mucosal pemphigus vulgaris, being evaluated in the Phase 1 DesCAARTes trial.
- Additional programs include MuSK-CAART, DSG3/1-CAART, FVIII-CAART and PLA2R-CAART, which remained in preclinical or IND-enabling development.
- The company relies substantially on the University of Pennsylvania and affiliated entities for research, development and manufacturing activities.
Financial condition and operating results
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $6.6 million | $4.6 million | +$1.9 million |
| General and administrative expense | $3.2 million | $3.3 million | -$0.1 million |
| Total operating expenses | $9.7 million | $7.9 million | +$1.8 million |
| Net loss | $9.7 million | $7.5 million | Loss increased $2.2 million |
| Net loss per share | $0.41 | $0.33 | Greater loss per share |
| Net cash used in operating activities | $8.7 million | $4.9 million | Cash use increased $3.7 million |
Operating losses represented substantially all operating activity; the filing does not provide a meaningful operating margin because the company had no revenue. Research and development spending increased primarily because of higher outsourced development services, personnel costs, clinical trial costs and sponsored research activities. Stock-based compensation was $1.3 million, compared with $0.9 million in the prior-year quarter.
- Cash and cash equivalents: $97.3 million at March 31, 2021, compared with $101.4 million at December 31, 2020.
- Short-term investments: $4.8 million; total cash, cash equivalents and investments: $102.0 million.
- Total assets: $107.3 million; total current liabilities: $4.0 million; stockholders’ equity: $103.3 million.
- Accumulated deficit: $76.0 million.
- The filing reports no credit facility or committed sources of capital and does not show material debt.
- Investing activities provided $2.4 million, principally from investment maturities, while financing activities provided $2.2 million from common-stock sales under the ATM program.
Material changes versus the prior comparable period
- R&D expense increased 42% to $6.6 million, driven by higher development services, personnel, clinical trial and sponsored research costs.
- Net loss increased 30% to $9.7 million, partly because interest income declined to $10 thousand from $410 thousand as interest rates fell.
- Operating cash burn increased to $8.7 million from $4.9 million.
- During Q1 2021, the company sold 194,189 common shares under its ATM program for $2.2 million of net proceeds.
- After quarter-end, the company sold an additional 671,369 shares for $7.3 million of net proceeds. Total 2021 ATM proceeds through the filing date were $9.5 million net.
- In January 2021, the company entered into a manufacturing agreement with WuXi for anticipated MuSK-CAART Phase 1 manufacturing; termination for convenience may require a $1.5 million fee.
- In February 2021, the company entered into a CHOP vector-manufacturing research agreement, with $448 thousand of remaining expected 2021 costs.
Guidance, outlook, management commentary and risks
- Management expects research and development and general and administrative expenses to increase substantially as programs advance, clinical trials continue and manufacturing capabilities are developed.
- Based on the operating plan, management believes cash, cash equivalents and investments at March 31, 2021, together with April ATM proceeds, will fund operations and capital requirements through at least the fourth quarter of 2022. The filing cautions that actual cash consumption could be faster than projected.
- Management expects to submit an IND for MuSK-CAART in the second half of 2021.
- The company expected acute safety data from the second and third DesCAARTes cohorts in the third and fourth quarters of 2021, respectively, and expected topline target-engagement data for the first cohort in the second half of 2021. These are forward-looking expectations, not financial guidance.
- The company expects to require substantial additional financing to complete clinical development and commercialize any product candidates. Future funding may come from equity, debt, collaborations, licensing or other sources and may dilute existing stockholders.
- COVID-19 had not materially affected financial results through March 31, 2021, but could delay trial enrollment, manufacturing, clinical-site activities, supply chains and capital raising.
- Key risks include early-stage clinical development, limited operating history, possible adverse clinical outcomes, patient enrollment and regulatory delays, complex manufacturing, dependence on Penn and other third parties, intellectual-property license risks, competition and the need for additional capital.
- The company reported no material litigation as of March 31, 2021, no material changes to contractual obligations from year-end, and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Progress, enrollment, safety findings and target engagement in the DesCAARTes DSG3-CAART trial.
- Whether the planned MuSK-CAART IND submission occurs in the second half of 2021 and whether the FDA permits clinical development to proceed.
- Actual quarterly cash burn, remaining cash runway and the timing and terms of future financings.
- Manufacturing-transfer progress from Penn to WuXi or other contract manufacturers, including vector supply and product comparability.
- Any changes to Penn license or sponsored research agreements, including milestone, royalty and termination provisions.
- Potential dilution from the remaining ATM capacity, equity compensation and future capital raises.
- Whether COVID-19, regulatory requirements or adverse events alter clinical timelines or development costs.